Member Info for grimshady

So help me out here is this the Nice recommendation which requires the NHS to find funding for it in 3 months?

or not?

Sound investing buying stuff at historic highs lmao

Think we are talking about two different things long.

the link John supplied to Innovate uk funding has Genedrive listed 4762 with 188k sometime early this year.

I am not talking about the funding in RNS. today.....which I think is in addition to that funding. Not that 200k makes a right lot of difference other than we would be unable to say how much of it was going direct to GDR and how much vis Manchester uni. Johns thinking was that GDR was getting this 188k direct and the rest 1M via MU. I not so sure. we see i guess

Sorry long which column are you looking at?

HI Long

Read it again and at no point does it say which test the £188k is for but it is dated earlier this year. it does state another total of £470k for project total.

Am I missing something long? wouldn't be first time.

@john

think that might be money for ALHI test rather than stroke test dated 1.4.23 when stroke test wasn't at validation stage.

not very clear what ever it is.

There should be some more money from Devote for ALHI test at some point to. It was one of three of devotes aims I think.

and RND tax return normally around £1million

also Nice said they were going to aid the validation process and if I remember rightly put together a group to do that be interesting to see how that works. wont be direct cash but maybe identifying grants like from Devote in different areas.+

add £1M form devote via Manchester Uni makes things a interesting

looks like Mr Creek likes a mid day RNS

is this the start of the much touted news flow? guess we will see

maybe we get more RNS info now maybe not :(

@john

thank you

Link please john

Hi John where did this come from?

link if you could please

Why if you are all so bad at investing, you have to moan about your loses here should anyone take anything any of you say seriously.

your obviously dreadful at trading !

:)

Link please

@johnlay****

and how exactly do you figure that out?

How can we have this scale of buys to sales and MM's not move price up?

Hope that is our new CEO buying in :)

Your right slacker Devote wont cover the whole of the monthly outgoings but it will cover a portion of it

In fact we know that a roll out of AHIL to the whole country would cover monthly out goings (though I thought they reduced those to around 300k but I may be wrong) and leave around a million spare.

but the stroke marker test is not far away and that has the potential to provide another slice of devote funding. which means less needed to cover those outgoings and that is just the North west area.

There will be similar pockets of funding from around the country for both products (we know NICE have formed a group to identify and aid GDR in funding the data collection phase) just to be clear NICE will not fund it (they don't do that).

The smaller the gap between this funding and the monthly outgoings the easier it is to bridge with sales and the longer the cash lasts.

The new CEO has sold into the NHS and has a solid sale back ground from what I can see, and surely they will have sales incentives in his contract. If I were him I would be looking at a few quick wins to steady investor nerves.

But saint that isn't what you have been saying is it?

Now I am pretty sure your doing this deliberately

There is no relationship between Devote funding and Nice recommendations. They could fund research in a new product if they wished a fact they stated in their aims and objectives.

AIHL is being sold by inspiration Healthcare right now in the UK. with out a full recommendation from nice !!

@saint

Again I not sure if you get it.

Nice are not a regulatory body.

They provide recommendations, guidelines and best practice advice. The NHS must when a product is given full recommendation find funding for that product within three months. (I think this is where confusion occurs). You may still be right about volume of sales until this is achieved but there will be early adopters like the Manchester trusts and some of these will be funded by organisations like Devote. How many and how much this brings in is utterly unknown at the minute.

@saint

I know what NICE does it seams you don't !

From the first page of their website "Evidence-based recommendations developed by independent committees, including professionals and lay members, and consulted on by stakeholders"

from RNS

"UKCA marking now allows the Company to begin commercialisation in the UK, and actively engage in the DEVOTE programme (previously announced in May 2023), which will generate additional performance data in an acute care setting. This expanded dataset is required for CE marking submission, which will allow for commercialisation in the EU. Submission is expected in the first half of 2024 once genedrive's engagement with DEVOTE has completed. In the United Kingdom, the Company will be selling the product through its direct sales team, and momentum for adoption is expected to be influenced by positive final NICE recommendations for CYP2C19 testing, which are expected in December 2023."

Maybe its you who should you back to basic's?

@spanner sorry slacker

https://www.lse.co.uk/rns/GDR/ukca-marking-achieved-for-new-cyp2c19-test-0lsrcundbefo1cg.html

very very poor job mate very very poor